Doctors just found a way to slow one of the deadliest prostate cancers

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay disease progression in men with specific DNA repair gene mutations. In the large AMPLITUDE trial, patients receiving the combo lived longer without symptoms worsening and saw nearly a 50% risk reduction in BRCA-mutated cases. While side effects like anemia were more common, the results mark a major step toward precision medicine for prostate cancer.